SOME BLOOD BIOCHEMICAL INDICES OF MICE WITH pttg GENE KNOCKOUT

O. P. Kanyuka, Ye. Z. Filyak, S. V. Afanasyev, N. O. Sybirna


DOI: http://dx.doi.org/10.30970/sbi.0503.178

Abstract


Liver injury of any etiology is accompanied by increased fibrogenesis. One of the key genes that may influence in the development of liver fibrosis, is pttg gene (Pituitary tumor transforming gene). This gene encodes a protein seсurin which plays an important role in the maintenance of sister chromatids in associated state in S-phase cell cycle. This pttg gene involved in regulation of such key events, as mitosis, reparation DNA, and apoptosis. The effect of pttg gene knockout on some bioche­mical parameters of blood serum of mice that can be serological markers of liver functional state, namely the activity of alanineaminotransferase, aspartateaminotransferase and lactate dehydrogenase, serum albumin concentration, total and direct bilirubin in blood serum of wild-type mice and mice with pttg gene knockout in different age groups of these animal.


Keywords


gene pttg, liver, fibrosis, bilirubin, lactate dehydrogenase

References


1. Бабак О.Я., Колесникова Е.В., Кравченко Н.А. Фиброз печени: современные представления о механизмах, способах диагностики и лечения. Сучасна гастроентерологія, 2009; 2: 5 -17.

2. Камышников В.С. Клинико-биохимическая лабораторная диагностика. Справочник: В 2-х т. Москва: Интерпрессервис, 2003. Т. 1. 495 с.

3. Лабораторные методы исследования в клинике. Под ред. В. В. Меньшикова. Москва: Медицина, 1987. 365 с.

4. Уикли Б. Электронная микроскопия. Москва, 1975. 324 с.

5. Afdhal N.H., Nunes D. Evaluation of liver fibrosis: A concise review. Am. J. Gastroenterol, 2004; 27: 1704-1713.

6. Balsano C., Alisi A.V. Liver fibrosis and therapeutic strategies: the goal for improving metabolism. Curr. Drug. Targets, 2009; 10(6): 505-512.
https://doi.org/10.2174/138945009788488459
PMid:19519352

7. Bataller R., Brenner D.A. Liver fibrosis. J. Clin. Invest, 2005;115: 209-218.
https://doi.org/10.1172/JCI200524282
PMid:15690074 PMCid:PMC546435

8. Calеs P., Lainе F., Boursier J. et al. Comparison of blood tests for liver fibrosis specific or not to NAFLD. J. of Hepatol, 2007; 50: 165-17.
https://doi.org/10.1016/j.jhep.2008.07.035
PMid:18977552

9. Davern T.J., Scharschmidt B.F. Biochemical liver tests. Feldman M., ed. Gastrointestinal and Liver Disease. V. 2. 7th ed. Philadelphia: W. B. Saunders, 2002.1227-1239.

10. De Ledinghen V., Le Bail B., Rebouissoux L. et al. Liver stiffness measurement in children using FibroScan: feasibility study and comparison with Fibrotest, aspartate transaminase to platelets ratio index, and liver biopsy. J. Pediatr. Gastroentorol. Nutr, 2007; 45: 443-450.
https://doi.org/10.1097/MPG.0b013e31812e56ff
PMid:18030211

11. Gianni E., Risso D., Botta F. et al. Validity and clinical utility of the aspartate aminiransferase_alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus_related chronic liver disease. Arch. Intern. Med, 2003; 163: 218-224.
https://doi.org/10.1001/archinte.163.2.218
PMid:12546613

12. Kim D.S., Franklyn J.A., Boelaert K. et al. Pituitary tumor transforming gene (pttg) stimulates thyroid cell proliferation via a vascular endothelial growth factor /kinase insert domain receptor/ inhibitor of DNA binding-3 autocrine pathway. J. of Clin. Endocrinol. and Metabolism, 2006; 91: 4603-4611.
https://doi.org/10.1210/jc.2006-1291
PMid:16926250

13. Laine F., Bendavid C., Moirand R. et al. Prediction of liver fibrosis in patients with features of the metabolic syndrome regardless of alcohol consumption. Hepatology, 2004; 39: 1639-1646.
https://doi.org/10.1002/hep.20219
PMid:15185305

14. Lee U.E., Ghiassi-Nejad Z., Paris A.J. et al. Tumor suppressor activity of KLF6 mediated by downregulation of the PTTG1 oncogene. FEBS Lett, 2010; 584(5) :1006-10.
https://doi.org/10.1016/j.febslet.2010.01.049
PMid:20116377 PMCid:PMC2827621

15. Pei L., Melmed S. Isolation and characterization of a pituitary tumor-transforming gene (pttg). Molecular Endocrinol, 1997; 11: 433-441.
https://doi.org/10.1210/mend.11.4.9911
PMid:9092795

16. Pratt D.S., Kaplan M.M. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N. Engl. J. Med, 2000;3 42(17): 1266-1271.
https://doi.org/10.1056/NEJM200004273421707
PMid:10781624

17. Rajamannan N.M., Subramaniam M., Abraham T.P. et al. TGFβ inducible early gene-1 (TIEG1) and cardiac hypertrophy: discovery and characterization of a novel signaling pathway. J. of Cell. Biochemistry, 2007; 100: 315-325.
https://doi.org/10.1002/jcb.21049
PMid:16888812 PMCid:PMC3927779

18. Salehi F., Kovacs K., Scheithauer B.W. et al. Pituitary tumor-transforming gene in endocrine and other neoplasms: a review and update. Endocrine-Related Cancer, 2008; 15(3): 721-743.
https://doi.org/10.1677/ERC-08-0012
PMid:18753362

19. Stoika R., Melmed S. Expression and function of pituitary tumour transforming gene for T-lymphocyte activation. Brit. J. of Haematology, 2002; 119: 1070-1074.
https://doi.org/10.1046/j.1365-2141.2002.03941.x
PMid:12472590

20. Zou H., McGarry TJ., Bernal T., Kirschner M.W. Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science, 1999; 285: 418-422.
https://doi.org/10.1126/science.285.5426.418
PMid:10411507


Refbacks

  • There are currently no refbacks.


Copyright (c) 2011 Studia biologica

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.